IP Library › Granted Patent US 10,716,817
Granted Patent B2
US 10,716,817 · App. 15/835,606 · Granted Jul 21, 2020

Antiviral methods and compositions comprising probiotic bacterial molecules

Inventor: Mansel Griffiths (Rockwood, CA)
Assignee: UNIVERSITY OF GUELPH
A61K35/747A23L33/135A61K9/19A61K35/741A61K38/07A61K38/08A61K45/06A61K47/26A23V2002/00Y02A50/463
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,817
App. No.
15/835,606
Granted
Jul 21, 2020
Kind
B2
Abstract

Molecules secreted or derived from probiotic bacteria are provided for use in compositions and methods for the treatment and/or prevention of infection by pathogenic viruses. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

Claims (25)

1. A method for reducing incidence and/or for treatment of Hepatitis virus infection in a subject, the method comprising administering an effective amount of a composition comprising molecules secreted by or derived from probiotic bacteria selected from the group consisting of Lactobacillus, Lactococcus , and combinations thereof, wherein the secreted molecules are peptides having from 2 to 10 amino acids.

2. The method of claim 1 , wherein said Lactobacillus is selected from the group consisting of Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus helveticus , and Lactobacillus plantarum.

3. The method of claim 1 , wherein said Lactococcus is Lactococcus lactis.

4. The method of claim 1 , wherein the Hepatitis virus infection is Hepatitis A virus and/or Hepatitis E virus.

5. The method of claim 1 , wherein the composition is combined within an edible food product, nutritional supplement and/or ingestible liquid.

6. The method of claim 1 , wherein the composition further comprises one or more strains of whole probiotic bacteria.

7. The method of claim 1 , wherein said secreted molecule is from Lactobacillus acidophilus.

8. The method of claim 7 , wherein said secreted molecule comprises a sequence selected from the group consisting of YPVEPF, YPPGGP, YPPG, NQPY, and combinations thereof.

9. The method of claim 1 , wherein the composition further comprises a sugar source.

10. The method of claim 9 , wherein the sugar source is glucose.

11. The method of claim 1 , further comprising administering one or more antivirals.

12. The method of claim 1 , wherein said composition is provided as a lyophilized culture fraction.

13. The method of claim 1 , wherein said molecules have one or more of the following characteristics: are proteinaceous; low molecular weight; and can withstand heating at up to about 90° C., freezing, thawing, lyophilization and/or spray drying.

14. The method of claim 1 , wherein the composition is a cell-free supernatant.

15. The method of claim 1 , wherein the composition comprises live probiotic bacteria from which the molecules are derived or secreted.

16. The method of claim 1 , wherein the composition comprises live probiotic bacteria other than the bacteria from which the molecules are derived or secreted.

17. The method of claim 1 , wherein the molecules in the composition are purified.

18. A method for reducing incidence and/or treatment of infections by Hepatitis virus in a subject, the method comprising administering to said subject an effective amount of a composition comprising one or more molecules secreted by or derived from a probiotic bacterium selected from the group consisting of Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus reuteri, Lactococcus lactis , and combinations thereof, wherein the secreted molecules are peptides having from 2 to 10 amino acids.

19. The method of claim 18 , wherein said secreted molecule comprises an amino acid sequence selected from the group consisting of YPVEPF, YPPGGP, YPPG, NQPY, and combinations thereof.

20. The method of claim 18 , wherein said method further comprises the administration of an antiviral.

21. A method for reducing the carriage by a food production animal of Hepatitis virus strains that cause human infection, said method comprising administering an effective amount of one or more secreted molecules from a probiotic bacterium selected from the group consisting of Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus reuteri, Lactococcus lactis , and combinations thereof to the food production animal prior to exposure to the Hepatitis virus strains that cause human infection, wherein the secreted molecules are peptides having from 2 to 10 amino acids.

22. A method of reducing propagation of a harmful Hepatitis virus in a food source, the method comprising applying an effective amount of a secreted molecule(s) from a probiotic bacteria selected from the group consisting of Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus reuteri, Lactococcus lactis , and combinations thereof to the food source, wherein the secreted molecules are peptides having from 2 to 10 amino acids.

23. The method of 22 , wherein said molecule comprises an amino acid sequence selected from the group consisting of YPVEPF, YPPGGP, YPPG, NQPY, and combinations thereof.

24. The method of claim 22 , wherein said molecule inhibits the propagation of Hepatitis A virus and/or Hepatitis E virus.

25. The method of claim 22 , wherein said method further comprises the administration of a probiotic bacterium.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2018
From: GRIFFITHS, MANSEL
To: UNIVERSITY OF GUELPH
Reel/Frame 045161/0886 →
Continuity (3)
Continuation 14457916 · Aug 12, 2014
Provisional Application 61865066 · Aug 12, 2013
Related Publication 20180177834A1 · Jun 28, 2018